In Brief
This article was originally published in The Gold Sheet
Executive Summary
Question-based review, or QbR, could spread from generics to new drugs. And that’s the way the patent crumbles: FDA’s new tablet-scoring guidance.
You may also be interested in...
FDA’s Tablet Scoring Final Guidance Requires Generics To Be Same As Brand
Generic industry concerns that scoring conventions could create barriers to entry did not win out in final tablet scoring guidance; FDA says to contact it if the scoring convention is patent protected.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.